Iovance Biotherapeutics, Inc. IOVA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $263.5M+60.6% | $164.07M+13,699% | $1.19M— | —— | ||
| $180.97M+67.7% | $107.94M— | —— | —— | ||
| $82.54M+47.0% | $56.13M+35,883% | $156K— | —— | ||
| 31.3%-2.9pp | 34.2%+21.1pp | 13.1%— | —— | ||
| $301.71M+7.8% | $279.91M-16.0% | $333.19M+13.0% | $294.78M+13.8% | ||
| $152.45M-0.1% | $152.62M+43.8% | $106.1M+1.9% | $104.1M+24.4% | ||
| —— | —— | —— | —— | ||
| $35.94M+44.6% | $24.86M+16.1% | $21.42M+130% | $9.31M+199% | ||
| $666.86M+19.2% | $559.35M+21.1% | $461.75M+15.8% | $398.88M+16.4% | ||
| -$403.36M-2.0% | -$395.28M+14.2% | -$460.56M-15.5% | -$398.88M-16.4% | ||
| -153.1%+87.8pp | -240.9%+38,494pp | -38,735%— | —— | ||
| $10.31M-49.2% | $20.27M+55.4% | $13.04M+337% | $2.99M+562% | ||
| -$393.05M-4.8% | -$375.01M+16.2% | -$447.52M-13.0% | -$395.89M-15.7% | ||
| -$2.26M— | —— | -$3.48M— | $0— | ||
| -$390.98M-5.1% | -$372.18M+16.2% | -$444.04M-12.2% | -$395.89M-15.7% | ||
| -148.4%+78.5pp | -226.8%+37,119pp | -37,345.4%— | —— | ||
| —— | -$1.29+31.4% | -$1.88+24.2% | -$2.48-11.7% | ||
| -$1.09+15.5% | -$1.29+31.4% | -$1.88+24.2% | -$2.48-11.7% | ||
| —— | 1.1B+24.5% | 919.1M+45.6% | 631.5M+3.5% | ||
| 1.4B+20.5% | 1.1B+24.5% | 919.1M+45.6% | 631.5M+3.5% | ||
| $7.29M— | —— | —— | —— | ||
| $26.96M— | —— | $34.93M— | —— | ||
| $27.33M— | —— | $27.7M— | —— | ||
| $263.5M+60.6% | $164.07M+13,699% | $1.19M— | —— | ||
| $61.58M-43.8% | $109.63M+75.1% | $62.63M-25.5% | $84.02M+20.4% | ||
| $61.58M-43.8% | $109.62M+75.0% | $62.63M— | —— | ||
| -$403.36M-2.0% | -$395.28M+14.2% | -$460.56M-15.5% | -$398.88M-16.4% | ||
| -$390.68M-2.0% | -$383.03M+14.7% | -$449.05M-15.3% | -$389.57M-14.7% | ||
| -$390.68M-2.0% | -$383.03M+14.7% | -$449.05M-15.3% | -$389.57M-14.7% | ||
| -148.3%+85.2pp | -233.5%+37,533pp | -37,766.7%— | —— | ||
| -$403.36M-2.0% | -$395.28M+14.2% | -$460.56M-15.5% | -$398.88M-16.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Gross margin is 36.7% and operating margin is -127.2%, with a -123.9% net margin.
- Where does Iovance Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.